{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:31:14Z","timestamp":1793853074837,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CORPG3J0332"],"award-info":[{"award-number":["CORPG3J0332"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CORPG3J0333"],"award-info":[{"award-number":["CORPG3J0333"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with <jats:italic>EGFR<\/jats:italic> subtype and generation of tyrosine kinase inhibitor (TKI) treatment, on patients\u2019 outcome. 553 metastatic <jats:italic>EGFR<\/jats:italic>-mutant NSCLC patients received front-line EGFR-TKI treatment. Progression-free survival (PFS), overall survival (OS) and secondary T790M rate were analysed. BM was observed in 211 (38.2%) patients. BM (HR 1.20 [95% CI 0.99\u20131.48]; p\u2009=\u20090.053), ECOG PS 0\u20131 (HR 0.71 [95% CI 0.54\u20130.93]; p\u2009=\u20090.014) and afatinib treatment (HR 0.81 [95% CI 0.66\u20130.99]; p\u2009=\u20090.045) were associated with PFS. Afatinib-treated patients without BM demonstrated a significantly longer PFS (16.3\u00a0months) compared to afatinib-treated patients with BM (13.7\u00a0months) and to gefitinib\/erlotinib-treated patients with (11.1\u00a0months) or without BM (14.2\u00a0months; p\u2009&lt;\u20090.001). CNS-only progression trended higher in afatinib-treated patients. ECOG PS 0\u20131 (HR 0.41 [95% CI 0.31\u20130.56]; p\u2009&lt;\u20090.001) and <jats:italic>EGFR<\/jats:italic> L858R mutation (HR 1.46 [95% CI 1.13\u20131.88]; p\u2009=\u20090.003), but not BM, were the predictors for OS. BM (OR 2.02 [95% CI 1.02\u20134.08]; p\u2009=\u20090.040), afatinib treatment (OR 0.26 [95% CI 0.12\u20130.50]; p\u2009&lt;\u20090.001) and <jats:italic>EGFR<\/jats:italic> L858R mutation (OR 0.55 [95% CI 0.28\u20131.05]; p\u2009=\u20090.070) were associated with secondary T790M rate. In BM patients, gefitinib\/erlotinib-treated ones with 19 deletion mutation and afatinib-treated ones with L858R mutation had the highest and the lowest T790M rate (94.4% vs. 27.3%, p\u2009&lt;\u20090.001), respectively. BM and generation of EGFR-TKI jointly impact PFS and secondary T790M rate in patients with <jats:italic>EGFR<\/jats:italic>-mutant NSCLC, whereas OS was mainly associated with <jats:italic>EGFR<\/jats:italic> subtype.<\/jats:p>","DOI":"10.1038\/s41598-023-45815-8","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T11:04:08Z","timestamp":1700564648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC"],"prefix":"10.1038","volume":"13","author":[{"given":"Jia-Shiuan","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen Chung-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-Hung","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hsien","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hsuan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"How-Wen","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Tsai","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Chih","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-Fu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ke","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsi Scott","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"issue":"suppl_1","key":"45815_CR1","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","volume":"29","author":"WH Hsu","year":"2018","unstructured":"Hsu, W. H. et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann. Oncol. 29(suppl_1), i3\u2013i9 (2018).","journal-title":"Ann. Oncol."},{"issue":"11","key":"45815_CR2","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.3390\/cells10113192","volume":"10","author":"Y Tsubata","year":"2021","unstructured":"Tsubata, Y., Tanino, R. & Isobe, T. Current therapeutic strategies and prospects for EGFR mutation-positive lung cancer based on the mechanisms underlying drug resistance. Cells 10(11), 3192 (2021).","journal-title":"Cells"},{"issue":"1","key":"45815_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-020-06805-5","volume":"20","author":"K Qin","year":"2020","unstructured":"Qin, K. et al. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: A meta-analysis. BMC Cancer 20(1), 328 (2020).","journal-title":"BMC Cancer"},{"issue":"5","key":"45815_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cllc.2021.01.002","volume":"22","author":"SWS Chan","year":"2021","unstructured":"Chan, S. W. S. et al. Systemic inflammatory markers of survival in epidermal growth factor-mutated non-small-cell lung cancer: Single-institution analysis, systematic review, and meta-analysis. Clin. Lung Cancer 22(5), 390\u2013407 (2021).","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"45815_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-017-2590-x","volume":"135","author":"M Ge","year":"2017","unstructured":"Ge, M. et al. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases. J. Neurooncol. 135(2), 413\u2013418 (2017).","journal-title":"J. Neurooncol."},{"issue":"4","key":"45815_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","volume":"20","author":"T Iuchi","year":"2015","unstructured":"Iuchi, T. et al. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int. J. Clin. Oncol. 20(4), 674\u2013679 (2015).","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"45815_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12885-019-5331-z","volume":"19","author":"WY Li","year":"2019","unstructured":"Li, W. Y. et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: A systematic review and meta-analysis. BMC Cancer 19(1), 145 (2019).","journal-title":"BMC Cancer"},{"issue":"2","key":"45815_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","volume":"9","author":"DY Shin","year":"2014","unstructured":"Shin, D. Y. et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J. Thorac. Oncol. 9(2), 195\u2013199 (2014).","journal-title":"J. Thorac. Oncol."},{"issue":"52","key":"45815_CR9","doi-asserted-by":"publisher","first-page":"90430","DOI":"10.18632\/oncotarget.19563","volume":"8","author":"SK Liang","year":"2017","unstructured":"Liang, S. K. et al. Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. Oncotarget 8(52), 90430\u201390443 (2017).","journal-title":"Oncotarget"},{"issue":"3","key":"45815_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","volume":"11","author":"M Schuler","year":"2016","unstructured":"Schuler, M. et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J. Thorac. Oncol. 11(3), 380\u2013390 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"45815_CR11","doi-asserted-by":"publisher","first-page":"175883592110357","DOI":"10.1177\/17588359211035710","volume":"13","author":"AC Huang","year":"2021","unstructured":"Huang, A. C. et al. First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Ther. Adv. Med. Oncol. 13, 17588359211035710 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"45815_CR12","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.2147\/CMAR.S322967","volume":"13","author":"CY Chang","year":"2021","unstructured":"Chang, C. Y. et al. Efficacy and prognosis of first-line EGFR-tyrosine kinase inhibitor treatment in older adults including poor performance status patients with EGFR-mutated non-small-cell lung cancer. Cancer Manag. Res. 13, 7187\u20137201 (2021).","journal-title":"Cancer Manag. Res."},{"issue":"6","key":"45815_CR13","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1016\/j.cllc.2020.05.019","volume":"21","author":"RGP Gijtenbeek","year":"2020","unstructured":"Gijtenbeek, R. G. P. et al. Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer. Clin. Lung Cancer 21(6), e647\u2013e653 (2020).","journal-title":"Clin. Lung Cancer"},{"key":"45815_CR14","first-page":"100795","volume":"80","author":"T Payen","year":"2021","unstructured":"Payen, T. et al. Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. Respir. Med. Res. 80, 100795 (2021).","journal-title":"Respir. Med. Res."},{"key":"45815_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32025","author":"YT Lin","year":"2018","unstructured":"Lin, Y. T. et al. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.32025 (2018).","journal-title":"Int. J. Cancer"},{"issue":"9","key":"45815_CR16","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1634\/theoncologist.2016-0331","volume":"22","author":"ZH Yao","year":"2017","unstructured":"Yao, Z. H. et al. Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib. Oncologist 22(9), 1075\u20131083 (2017).","journal-title":"Oncologist"},{"issue":"1","key":"45815_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382(1), 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"45815_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi, M. et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N. Engl. J. Med. 389(2), 137\u2013147 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"45815_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park, K. et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17(5), 577\u2013589 (2016).","journal-title":"Lancet Oncol."},{"issue":"11","key":"45815_CR20","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1002\/ijc.32025","volume":"144","author":"YT Lin","year":"2019","unstructured":"Lin, Y. T. et al. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int. J. Cancer 144(11), 2887\u20132896 (2019).","journal-title":"Int. J. Cancer"},{"issue":"7","key":"45815_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3727\/096504018X15151523767752","volume":"26","author":"A Fujiwara","year":"2018","unstructured":"Fujiwara, A. et al. A retrospective comparison of the clinical efficacy of gefitinib, erlotinib, and afatinib in japanese patients with non-small cell lung cancer. Oncol. Res. 26(7), 1031\u20131036 (2018).","journal-title":"Oncol. Res."},{"issue":"2","key":"45815_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares, L. et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial. Ann. Oncol. 28(2), 270\u2013277 (2017).","journal-title":"Ann. Oncol."},{"issue":"11","key":"45815_CR23","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu, Y. L. et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. Lancet Oncol. 18(11), 1454\u20131466 (2017).","journal-title":"Lancet Oncol."},{"issue":"5","key":"45815_CR24","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.21037\/tlcr-20-379","volume":"9","author":"HA Jung","year":"2020","unstructured":"Jung, H. A. et al. The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. Transl. Lung Cancer Res. 9(5), 1749\u20131758 (2020).","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"45815_CR25","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1186\/s12885-018-5110-2","volume":"18","author":"WL Tan","year":"2018","unstructured":"Tan, W. L. et al. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer 18(1), 1198 (2018).","journal-title":"BMC Cancer"},{"issue":"5","key":"45815_CR26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2018.0049","volume":"4","author":"S Hong","year":"2018","unstructured":"Hong, S. et al. Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer. JAMA Oncol. 4(5), 739\u2013742 (2018).","journal-title":"JAMA Oncol."},{"issue":"3","key":"45815_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jtho.2016.09.001","volume":"12","author":"MB Barnet","year":"2017","unstructured":"Barnet, M. B. et al. EGFR-co-mutated advanced NSCLC and response to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 12(3), 585\u2013590 (2017).","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"45815_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jtho.2016.11.2225","volume":"12","author":"N Sutiman","year":"2017","unstructured":"Sutiman, N. et al. EGFR mutation subtypes influence survival outcomes following first-line gefitinib therapy in advanced Asian NSCLC patients. J. Thorac. Oncol. 12(3), 529\u2013538 (2017).","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"45815_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2013.07.003","volume":"82","author":"K Goto","year":"2013","unstructured":"Goto, K. et al. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer 82(1), 109\u2013114 (2013).","journal-title":"Lung Cancer"},{"issue":"4","key":"45815_CR30","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/ijc.33821","volume":"150","author":"CH Huang","year":"2022","unstructured":"Huang, C. H. et al. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. Int. J. Cancer 150(4), 626\u2013635 (2022).","journal-title":"Int. J. Cancer"},{"issue":"9","key":"45815_CR31","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00432-020-03296-6","volume":"146","author":"WQ Li","year":"2020","unstructured":"Li, W. Q. & Cui, J. W. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: Distinct mechanisms, different efficacies to treatments. J. Cancer Res. Clin. Oncol. 146(9), 2329\u20132338 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"45815_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.lungcan.2020.10.018","volume":"150","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors. Lung Cancer 150, 178\u2013185 (2020).","journal-title":"Lung Cancer"},{"issue":"7","key":"45815_CR33","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/sj.bjc.6602102","volume":"91","author":"JM Satagopan","year":"2004","unstructured":"Satagopan, J. M. et al. A note on competing risks in survival data analysis. Br. J. Cancer 91(7), 1229\u20131235 (2004).","journal-title":"Br. J. Cancer"},{"issue":"446","key":"45815_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94(446), 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"issue":"8","key":"45815_CR35","first-page":"4177","volume":"37","author":"A Tamiya","year":"2017","unstructured":"Tamiya, A. et al. Cerebrospinal fluid penetration rate and efficacy of Afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: A multicenter prospective study. Anticancer Res. 37(8), 4177\u20134182 (2017).","journal-title":"Anticancer Res."},{"issue":"3","key":"45815_CR36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","volume":"70","author":"Y Togashi","year":"2012","unstructured":"Togashi, Y. et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother. Pharmacol. 70(3), 399\u2013405 (2012).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"45815_CR37","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross, D. A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4(9), 1046\u20131061 (2014).","journal-title":"Cancer Discov."},{"key":"45815_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.lungcan.2020.12.008","volume":"152","author":"W Peng","year":"2021","unstructured":"Peng, W. et al. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report. Lung Cancer 152, 66\u201370 (2021).","journal-title":"Lung Cancer"},{"issue":"3","key":"45815_CR39","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ijrobp.2019.02.051","volume":"104","author":"E Miyawaki","year":"2019","unstructured":"Miyawaki, E. et al. Optimal sequence of local and EGFR-TKI therapy for EGFR-mutant non-small cell lung cancer with brain metastases stratified by number of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 104(3), 604\u2013613 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"45815_CR40","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","volume":"21","author":"R Shah","year":"2020","unstructured":"Shah, R. & Lester, J. F. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non-small-cell lung cancer: A clash of the generations. Clin. Lung Cancer 21(3), e216\u2013e228 (2020).","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"45815_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/annonc\/mdt573","volume":"25","author":"HA Yu","year":"2014","unstructured":"Yu, H. A. et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann. Oncol. 25(2), 423\u2013428 (2014).","journal-title":"Ann. Oncol."},{"issue":"15_suppl","key":"45815_CR42","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1200\/jco.2014.32.15_suppl.8075","volume":"32","author":"YJ Lee","year":"2014","unstructured":"Lee, Y. J., Lee, G. K. & Lee, Y.-S. Clinicopathologic features of lung cancer patients harboring de novo EGFR T790M mutation. J. Clin. Oncol. 32(15_suppl), 8075\u20138075 (2014).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"45815_CR43","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.4143\/crt.2017.512","volume":"50","author":"YH Huang","year":"2018","unstructured":"Huang, Y. H. et al. The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Cancer Res. Treat. 50(4), 1294\u20131303 (2018).","journal-title":"Cancer Res. Treat."},{"key":"45815_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.07.007","volume":"101","author":"K Nosaki","year":"2016","unstructured":"Nosaki, K. et al. Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung Cancer 101, 1\u20138 (2016).","journal-title":"Lung Cancer"},{"issue":"2","key":"45815_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40487-018-0064-8","volume":"6","author":"T Seto","year":"2018","unstructured":"Seto, T. et al. Real-world EGFR T790M testing in advanced non-small-cell lung cancer: A prospective observational study in Japan. Oncol. Ther. 6(2), 203\u2013215 (2018).","journal-title":"Oncol. Ther."},{"key":"45815_CR46","doi-asserted-by":"publisher","first-page":"175883592199650","DOI":"10.1177\/1758835921996509","volume":"13","author":"N Magios","year":"2021","unstructured":"Magios, N. et al. Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Ther. Adv. Med. Oncol. 13, 1758835921996509 (2021).","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45815-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45815-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45815-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T11:34:26Z","timestamp":1700566466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45815-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45815"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45815-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CS-K received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Roche, Pfizer, Eli Lilliy, Novartis, OnO Pharma, Chugai, Merck, Janssen Pharma, Takeda and Guardant Health. CS-K provided consultation for AstraZeneca, Boehringer Ingelheim, Eli Lilliy, Merck, Chugai, Takeda, Novartis and Guardant Health. None of the other authors have any conflict of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20323"}}